Terms: = Breast cancer AND TCL1A, P56279, 8115, ENSG00000100721, TCL1 AND Treatment
11 results:
1. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract] [Full Text] [Related]
2. Genetic predictors to acupuncture response for hot flashes: an exploratory study of breast cancer survivors.
Romero SAD; Li QS; Orlow I; Gonen M; Su HI; Mao JJ
Menopause; 2020 Aug; 27(8):913-917. PubMed ID: 32217888
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Underpinnings of Musculoskeletal Pain During treatment With Aromatase Inhibitors for breast cancer: A Biological Pathway Analysis.
Zhu Y; Koleck TA; Bender CM; Conley YP
Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
[TBL] [Abstract] [Full Text] [Related]
4. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
Cramer SL; Saha A; Liu J; Tadi S; Tiziani S; Yan W; Triplett K; Lamb C; Alters SE; Rowlinson S; Zhang YJ; Keating MJ; Huang P; DiGiovanni J; Georgiou G; Stone E
Nat Med; 2017 Jan; 23(1):120-127. PubMed ID: 27869804
[TBL] [Abstract] [Full Text] [Related]
5. Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.
Zhu X; Zhao H; Lin Z; Zhang G
Cancer Gene Ther; 2015 Dec; 22(12):573-80. PubMed ID: 26494558
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacogenetics of aromatase inhibitors.
Hadfield KD; Newman WG
Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
[TBL] [Abstract] [Full Text] [Related]
7. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (tcl1a) gene-mediated regulation of cytokine expression.
Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
[TBL] [Abstract] [Full Text] [Related]
8. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract] [Full Text] [Related]
9. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract] [Full Text] [Related]
10. Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress.
Balatoni CE; Dawson DW; Suh J; Sherman MH; Sanders G; Hong JS; Frank MJ; Malone CS; Said JW; Teitell MA
Am J Pathol; 2009 Oct; 175(4):1653-61. PubMed ID: 19717643
[TBL] [Abstract] [Full Text] [Related]
11. Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.
Dillman RO; Beutel LD; De Leon C; Nayak SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):205-11. PubMed ID: 11471485
[TBL] [Abstract] [Full Text] [Related]
